Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/30/2019 (Estimated)
OptionableOptionable
Can-Fite Biopharma (NASDAQ:CANF) Frequently Asked Questions
What is Can-Fite Biopharma's stock symbol?
Can-Fite Biopharma trades on the NASDAQ under the ticker symbol "CANF."
How were Can-Fite Biopharma's earnings last quarter?
Can-Fite Biopharma Ltd (NASDAQ:CANF) issued its earnings results on Wednesday, May, 29th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.94) by $0.74. The firm earned $0.30 million during the quarter. View Can-Fite Biopharma's Earnings History.
When is Can-Fite Biopharma's next earnings date?
What is the consensus analysts' recommendation for Can-Fite Biopharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Can-Fite Biopharma.
Has Can-Fite Biopharma been receiving favorable news coverage?
Media headlines about CANF stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Can-Fite Biopharma earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Can-Fite Biopharma.
Who are some of Can-Fite Biopharma's key competitors?
Some companies that are related to Can-Fite Biopharma include Briacell Therapeutics (BCT), Prescient Therapeutics (PTX), biOasis Technologies (BTI), Ixico (IXI), Bio-Gene Technology (BGT), Fusion Antibodies (FAB), Anatara Lifesciences (ANR), Ibio (IBIO), Naturally Splendid Enterprises (NSP), Realm Therapeutics (RLM), Bioxyne (BXN), BTC Health (BTC), Trillium Therapeutics (TRIL), Suda Pharmaceuticals (SUD) and Living Cell Technologies (LCT).
What other stocks do shareholders of Can-Fite Biopharma own?
Who are Can-Fite Biopharma's key executives?
Can-Fite Biopharma's management team includes the folowing people:
- Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)
- Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
- Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)
- Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director
- Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor
How do I buy shares of Can-Fite Biopharma?
Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Can-Fite Biopharma's stock price today?
One share of CANF stock can currently be purchased for approximately $3.19.
How big of a company is Can-Fite Biopharma?
What is Can-Fite Biopharma's official website?
MarketBeat Community Rating for Can-Fite Biopharma (NASDAQ CANF)
MarketBeat's community ratings are surveys of what our community members think about Can-Fite Biopharma and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
